NASDAQ:NVAX - Novavax Stock Price, Forecast & News

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax's stock reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

Novavax, Inc. (NASDAQ:NVAX) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.98) by $0.24. The biopharmaceutical company earned $2.51 million during the quarter, compared to analysts' expectations of $4.40 million. During the same quarter in the previous year, the business earned ($2.40) earnings per share. View Novavax's Earnings History.

Novavax is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Novavax.

9 analysts have issued 12 month target prices for Novavax's shares. Their forecasts range from $7.00 to $27.50. On average, they anticipate Novavax's share price to reach $15.93 in the next year. This suggests a possible upside of 106.3% from the stock's current price. View Analyst Price Targets for Novavax.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novavax.

News stories about NVAX stock have been trending negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Novavax earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the next few days. View News Stories for Novavax.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Egalet (EGLT), EXACT Sciences (EXAS), Palo Alto Networks (PANW), Akebia Therapeutics (AKBA), TG Therapeutics (TGTX), Cara Therapeutics (CARA), Trevena (TRVN), Gilead Sciences (GILD), Ocular Therapeutix (OCUL) and Opko Health (OPK).

Novavax's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (1.33%), Charles Schwab Investment Management Inc. (0.46%), Bank of New York Mellon Corp (0.40%), TSP Capital Management Group LLC (0.39%), Ladenburg Thalmann Financial Services Inc. (0.14%) and Virtu Financial LLC (0.13%). Company insiders that own Novavax stock include Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck. View Institutional Ownership Trends for Novavax.

NVAX stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Bank of America Corp DE, Virtu Financial LLC, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Sargent Investment Group LLC and Sargent Investment Group LLC. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III, John Trizzino and Michael A Mcmanus Jr. View Insider Buying and Selling for Novavax.

NVAX stock was acquired by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, Ikarian Capital LLC, UBS Group AG, Raymond James & Associates, Ladenburg Thalmann Financial Services Inc., Charles Schwab Investment Management Inc., Barclays PLC and State Street Corp. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, John Trizzino, Rachel K King and Stanley C Erck. View Insider Buying and Selling for Novavax.

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVAX stock can currently be purchased for approximately $7.72.

Novavax has a market capitalization of $247.97 million and generates $34.29 million in revenue each year. The biopharmaceutical company earns $-184,750,000.00 in net income (profit) each year or ($10.00) on an earnings per share basis. Novavax employs 373 workers across the globe.View Additional Information About Novavax.

The official website for Novavax is http://www.novavax.com/.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]